EverSource Wealth Advisors’s Nuvectis Pharma NVCT Stock Holding History

EverSource Wealth Advisors’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$993	Buy	54 +52	+2,600%	+$582	﹤0.01%	3963
2026 Q1	$16	Buy	+2	New	+$17	﹤0.01%	4361
2025 Q4	–	Sell	-76	Closed	-$458	–	4386
2025 Q3	$458	Sell	76 -20	-21%	-$137	﹤0.01%	3969
2025 Q2	$717	Buy	+96	New	+$871	﹤0.01%	3811

Other funds holding NVCT

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

AWM

Austin Wealth Management Austin, Texas $473M AUM 18.73% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

EverSource Wealth Advisors's NVCT Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Nuvectis Pharma (NVCT) stake by 2,600% in Q2 2026, buying an estimated $582 and bringing the position to 54 shares worth $993. The position accounts for ﹤0.01% of the portfolio, ranked #3963.

EverSource Wealth Advisors first reported a position in NVCT in Q2 2025 and has held it in 4 quarters since. 17 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

EverSource Wealth Advisors held 54 shares of Nuvectis Pharma worth $993 as of Q2 2026.
EverSource Wealth Advisors bought 52 Nuvectis Pharma shares in Q2 2026, an estimated $582.
Nuvectis Pharma made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3963 holding.
EverSource Wealth Advisors first reported a position in Nuvectis Pharma in Q2 2025 and has held it in 4 quarters since.
17 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.